Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC

Newsfeed Image, Light Gray Text On Dark Gray Background
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma (HCC).

Read more . . .